Investor Two Seas Capital LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Two Seas Capital LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-09-05 13D/A INDV / Indivior PLC 11,662,308 10,329,152
2025-08-13 13G ESPR / Esperion Therapeutics, Inc. 6,584,278 9,954,975
2025-08-13 13G GCI / Gannett Co., Inc. 11,230,621
2025-08-13 13G CLMT / Calumet, Inc. 4,497,609
2025-08-13 13G/A ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) 123,178,110 135,484,206
2025-08-13 13G/A AVDL / Avadel Pharmaceuticals plc 4,946,449 6,155,074
2025-08-13 13G ABUS / Arbutus Biopharma Corporation 8,387,388 10,443,317
2025-08-13 13G/A OMEX / Odyssey Marine Exploration, Inc. 2,953,690 3,154,808
2025-08-08 13D CORZ / Core Scientific, Inc. 19,122,842
2025-08-08 13D CORZ / Core Scientific, Inc. 19,122,842
2025-07-29 13D/A INDV / Indivior PLC 12,084,677 11,662,308
2025-07-14 13D/A INDV / Indivior PLC 12,072,398 12,084,677
2025-06-18 13D/A INDV / Indivior PLC 11,880,926 12,072,398
2025-05-22 13D/A INDV / Indivior PLC 11,579,819 11,880,926
2025-05-15 13G/A OMEX / Odyssey Marine Exploration, Inc. 2,947,747 2,953,690
2025-05-15 13G/A ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) 89,010,876 123,178,110
2025-05-15 13G AVDL / Avadel Pharmaceuticals plc 4,946,449
2025-03-04 13D/A INDV / Indivior PLC 12,007,514 11,579,819
2025-02-14 13G/A OMEX / Odyssey Marine Exploration, Inc. 1,816,384 2,947,747
2025-02-14 13G ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) 89,010,876
2025-01-17 13D/A INDV / Indivior PLC 13,030,027 12,007,514
2024-11-14 13G/A OMEX / Odyssey Marine Exploration, Inc. 2,082,638 1,816,384
2024-11-14 13G/A ESPR / Esperion Therapeutics, Inc. 7,686,120 6,584,278
2024-11-14 13G/A ABUS / Arbutus Biopharma Corporation 9,041,927 8,387,388
2024-10-17 13D/A INDV / Indivior PLC 13,260,025 13,030,027
2024-06-21 13D/A INDV / Indivior PLC 13,555,139 13,260,025
2024-03-29 13D/A INDV / Indivior PLC 13,670,312 13,555,139
2024-02-14 13G/A ESPR / Esperion Therapeutics, Inc. 7,922,170 7,686,120
2024-02-14 13G/A ABUS / Arbutus Biopharma Corporation 9,503,103 9,041,927
2024-02-14 13G/A OMEX / Odyssey Marine Exploration, Inc. 2,012,827 2,082,638
2023-11-21 13G ABUS / Arbutus Biopharma Corporation 9,503,103
2023-10-05 13G ESPR / Esperion Therapeutics, Inc. 7,922,170
2023-10-02 13D INDV / Indivior PLC 13,670,312
2023-02-13 13G/A OMEX / Odyssey Marine Exploration, Inc. 1,202,622 2,012,827
2022-02-11 13G/A OMEX / Odyssey Marine Exploration, Inc. 1,169,163 1,202,622
2021-02-10 13G/A OMEX / Odyssey Marine Exploration, Inc. 1,169,163
2020-09-01 13G OMEX / Odyssey Marine Exploration, Inc.